TabsDetailsBasic DetailsDate Posted: Tuesday, October 29, 2019Status: CompleteMedical Product: hydroxyprogesterone caproate, progesteroneHealth Outcome(s): exposure in pregnancyDescription: Our objective was to estimate use of hydroxyprogesterone caproate and progesterone during the second or third trimesters among pregnancies that ended with a live-birth delivery in the Sentinel Distributed Database (SDD). We identified live-birth deliveries occurring between January 1, 2008 to April 30, 2019. We distributed this request on August 5, 2019 to 15 Data Partners contributing to the SDD. Read More Deliverables (1)Sentinel Modular Program Report: Hydroxyprogesterone Caproate and Progesterone Use During PregnancyAdditional InformationAdditional DetailsFDA Center: CDERTime Period: January 1, 2008 - April 30, 2019Study Type: Modular ProgramAssessment Type: Exploratory AnalysesPopulation / Cohort: Females 10 to 54 years of ageData Sources: Sentinel Distributed Database (SDD)Related Links: Meeting of the Bone, Reproductive and Urologic Drugs Advisory Committee: Makena Use During PregnancyICPE 2020 Presentation: Use of Hydroxyprogesterone Caproate and Progesterone During the 2nd and/or 3rd Trimester Among Pregnancies with Live Birth Deliveries in the Sentinel Distributed Database
